Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes
Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes.
MK Ladumor, F Storelli, X Liang, Y Lai… - CPT …, 2022 - europepmc.org
Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
[HTML][HTML] Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes
MK Ladumor, F Storelli, X Liang, Y Lai… - CPT …, 2023 - ncbi.nlm.nih.gov
Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes
MK Ladumor, F Storelli, X Liang, Y Lai… - CPT …, 2023 - search.proquest.com
Physiologically based pharmacokinetic models, populated with drug-metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes
MK Ladumor, F Storelli, X Liang… - CPT …, 2023 - pubmed.ncbi.nlm.nih.gov
Physiologically based pharmacokinetic models, populated with drug-metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes.
MK Ladumor, F Storelli, X Liang, Y Lai… - CPT …, 2022 - europepmc.org
Physiologically based pharmacokinetic models, populated with drug-metabolizing enzyme
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …
and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment …